Nxstage Medical (NXTM) 13.25 $NXTM
Nasdaq stocks posting largest percentage increases
AP - Fri May 09, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
NxStage Reports Record First Quarter 2014 Financial Results And Exceeds Guidance
PR Newswire - Thu May 08, 6:22AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported record first quarter financial results that exceed the top end of its guidance range.
8.1% Return Seen to Date on SmarTrend NxStage Medical Call (NXTM)
Comtex SmarTrend(R) - Wed May 07, 5:22PM CDT
SmarTrend identified a Downtrend for NxStage Medical (NASDAQ:NXTM) on March 28th, 2014 at $12.43. In approximately 1 month, NxStage Medical has returned 8.13% as of today's recent price of $11.42.
Technical Roundup on Health Care Stocks -- Research on Amarin, United Therapeutics, Hologic, and NxStage Medical
PR Newswire - Fri Apr 25, 1:10PM CDT
On Thursday, April 24, 2014, the NASDAQ Composite ended at 4,148.34, up 0.52%, the Dow Jones Industrial Average finished the day flat at 16,501.65, and the S&P 500 closed at 1,878.61, up 0.17%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.80, down 0.20%, while the index has advanced 0.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR), Hologic Inc. (NASDAQ: HOLX) and NxStage Medical Inc. (NASDAQ: NXTM). Free technical research on AMRN, UTHR, HOLX and NXTM can be downloaded upon signing up at:
NxStage Patient Enjoys Travel and Active Lifestyle
PR Newswire - Tue Apr 15, 7:15AM CDT
NxStage Medical Inc., (NASDAQ: NXTM), a leading manufacturer of innovative home dialysis products, is proud to share current NxStage patient Henning's story of resilience and strength. For Henning, who has spent his life pursuing active and athletic endeavors around the world, more frequent home hemodialysis (HHD) with the NxStage® System One(TM) proved to be a good personal fit. Henning, a Danish citizen, has regained control of his life thanks to home hemodialysis. Currently he and his wife spend the majority of their time in New Hampshire and travel with the NxStage System One.
FDA Recommendations, Study Publications, Recognitions, Agreements, and Acquisitions - Analyst Notes on MannKind, Acceleron, Steris, Retrophin, and NxStage Medical
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ: XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX), and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
NxStage® to Report First Quarter 2014 Financial Results
PR Newswire - Tue Apr 08, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the first quarter ended March 31, 2014, on Thursday, May 8, 2014, before the opening of the financial markets.
Equities Updates on Top Gainers -- Research on Fresh Market, Alliance Fiber Optic Products, NxStage Medical, and UQM Technologies
PR Newswire - Thu Apr 03, 7:59AM CDT
On Wednesday, April 02, 2014, the US markets saw a positive sentiment, with the NASDAQ Composite closing at 4,276.46, up 0.20%, the Dow Jones Industrial Average ending the session at 16,573.00, up 0.24% and the S&P 500 edging 0.29% higher to finish the trading session at 1,890.90. The session saw a positive impact from Consumer Discretionary, Materials and Industrials sectors along with a drag from Information Technology, and Utilities sectors. A number of stocks saw large movements, including The Fresh Market Inc. (NASDAQ: TFM), Alliance Fiber Optic Products Inc. (NASDAQ: AFOP), NxStage Medical Inc. (NASDAQ: NXTM) and UQM Technologies Inc. (NYSE MKT: UQM). Free technical research on TFM, AFOP, NXTM and UQM can be downloaded upon signing up at:
NxStage Wins 2014 American Red Cross Northeast Chapter Workplace Hero Award
PR Newswire - Mon Mar 31, 7:37AM CDT
NxStage Medical Inc., a leading manufacturer of home dialysis products, today announced the Company has been awarded the 2014 Workplace Hero Award by the Northeast Chapter of the American Red Cross. Recognized for its commitment to community service over the course of 2013, NxStage distinguished itself from industry peers through continuous efforts to provide support for the disadvantaged and dedication to preparing employees to volunteer in the event of local and national disasters. The American Red Cross Northeast Chapter presented the award to NxStage for the first time at the 12th Annual Community Heroes Breakfast at the Doubletree by Hilton in Danvers, Massachusetts on March 20, 2014.
Uptrend Call Working As NxStage Medical Stock Rises 10.4% (NXTM)
Comtex SmarTrend(R) - Thu Mar 27, 9:31AM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on January 9th, 2014 at $11.37. In approximately 3 months, NxStage Medical has returned 10.38% as of today's recent price of $12.55.
NxStage Establishes First Annual National Home Hemodialysis Day
PR Newswire - Thu Mar 20, 7:00AM CDT
To build awareness for National Kidney Month, NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the first annual National Home Hemodialysis Day taking place today, March 20, 2014. In partnership with local and national kidney patient organizations, NxStage is encouraging the more than 26 million Americans1 that may have kidney disease and their supporters to wear a green ribbon to spread the word about kidney disease treatment options including home hemodialysis. In conjunction with this campaign, the Company is launching a national patient-to-patient outreach program called NxStage® + One(TM). This innovative initiative is based on the premise that one-to-one communication is the most compelling way to spread the word about the benefits of home hemodialysis.
NxStage Medical Up 21.6% Since SmarTrend Uptrend Call (NXTM)
Comtex SmarTrend(R) - Wed Mar 19, 5:00PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on January 9th, 2014 at $11.37. In approximately 2 months, NxStage Medical has returned 21.64% as of today's recent price of $13.83.
Uptrend Call Working As NxStage Medical Stock Rises 21.8% (NXTM)
Comtex SmarTrend(R) - Wed Mar 12, 11:06AM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on January 9th, 2014 at $11.37. In approximately 2 months, NxStage Medical has returned 21.81% as of today's recent price of $13.85.
Downgrade Alert for NxStage Medical (NXTM)
Comtex SmarTrend(R) - Tue Mar 11, 6:58AM CDT
NxStage Medical (NASDAQ:NXTM) was downgraded from Market Perform to Underperform at Wells Fargo today. The stock closed yesterday at $14.66 on volume of 1.3 million shares, above average daily volume of 497,000. In the past 52 weeks, NxStage Medical share prices have been bracketed by a low of $8.77 and a high of $15.00 and closed yesterday at $14.66, 67% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 2.2% while the 200-day MA has remained constant.
US Market for Dialysis Equipment and Concentrates
M2 - Thu Mar 06, 3:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/npv4t6/u_s_market_for) has announced the addition of the "U.S. Market for Dialysis Equipment and Concentrates" report to their offering. The Total Dialysis Device And Concentrates Market Will Grow To A Value Of Almost $2 Billion By 2020 The total dialysis device and concentrates market includes the markets for hemodialysis machines, dialysis catheters, dialysis concentrates, dialyzers, dialyzer reprocessing machines, bloodlines, AV fistula needles, AV grafts, declotting devices, guidewires, introducer sheaths and water treatment systems. The market will grow as a result of increased patient populations. The patient populations of traditional incenter hemodialysis, home hemodialysis (HHD) and peritoneal dialysis are expected to grow over the forecast period. There will also be strong growth in the dry concentrates and heat disinfectant water treatment system market. Scope of the Report - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback & Market Monitoring Reasons To Buy This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on a 'ground up' approach, which includes primary and secondary research methods. This report forecasts the development of the US market up to 2020. Key Topics Covered - Executive Summary - Research Methodology - US Dialysis Device And Concentrates Market - Hemodialysis Machine Market - Dialysis Catheter Market - Dialysis Concentrates Market - Dialyzer Market - Dialyzer Reprocessing Machine Market - Hemodialysis Bloodline And Tubing Set Market - Av Fistula Needle Market - Av Access Graft Market - Declotting Device Market - Introducer Sheath And Guidewire Market - Water Treatment System Market Companies Mentioned - AmeriWater - AngioDynamics - Argon Medical - Asahi Kasei Medical - B. Braun - Baxter - C. R. Bard - Cook Medical - Cordis - Covidien - Edwards Lifesciences - Fresenius - Gambro - Kawasumi Laboratories - LeMaitre - MAKY - MEDRAD - Mar Cor - Medcomp - Medisystems (NxStage Medical) - Medivators - NxStage Medical - Rockwell - Teleflex Medical - Terumo, - Vascular - W. L. Gore For more information visit http://www.researchandmarkets.com/research/np...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Shares of NXTM Up 25.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 05, 9:41AM CST
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on January 9th, 2014 at $11.37. In approximately 2 months, NxStage Medical has returned 25.95% as of today's recent price of $14.32.
U.S. Market for Dialysis Equipment and Concentrates (Executive Summary)
M2 - Fri Feb 28, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbwzlh/u_s_market_for) has announced the addition of the U.S. Market for Dialysis Equipment and Concentrates (Executive Summary) report to their offering. This executive summary relates to the report U.S. Market for Dialysis Equipment and Concentrates. The total dialysis device and concentrates market will grow to a value of almost $2 billion over the forecast period. The total dialysis device and concentrates market includes the markets for hemodialysis machines, dialysis catheters, dialysis concentrates, dialyzers, dialyzer reprocessing machines, bloodlines, AV fistula needles, AV grafts, declotting devices, guidewires, introducer sheaths and water treatment systems. The market will grow as a result of increased patient populations. The patient populations of traditional incenter hemodialysis, home hemodialysis (HHD) and peritoneal dialysis are expected to grow over the forecast period. There will also be strong growth in the dry concentrates and heat disinfectant water treatment system market. This report pertains to a forecast period of 10 years (2010 - 2020) for the U.S. market. Scope of the Report - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback & Market Monitoring Main Segments Included - U.S. Dialysis Device and Concentrates Market - Hemodialysis Machine Market - Dialysis Catheter Market - Dialysis Concentrates Market - Dialyzer Market - Dialyzer Reprocessing Machine Market - Hemodialysis Bloodline and Tubing Set Market - AV Fistula Needle Market - AV Access Graft Market - Declotting Device Market - Introducer Sheath and Guidewire Market - Water Treatment System Market Reasons To Buy This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on a 'ground up' approach, which includes primary and secondary research methods. * Please note this is an executive summary only. The full report is available for purchase by following the link below. Key Topics Covered: 1. Executive Summary 1.1 U.S. Dialysis Device And Concentrates Market 1.2 Hemodialysis Machine Market 1.3 Dialysis Catheter Market 1.4 Dialysis Concentrates Market 1.5 Dialyzer Market 1.6 Dialyzer Reprocessing Machine Market 1.7 Hemodialysis Bloodline And Tubing Set Market 1.8 Av Fistula Needle Market 1.9 Av Access Graft Market 1.10 Declotting Device Market 1.11 Introducer Sheath And Guidewire Market 1.12 Water Treatment System Market 1.13 Competitive Analysis Companies Mentioned: - AmeriWater - AngioDynamics - Argon Medical - Asahi Kasei Medical - B. Braun - Baxter - C. R. Bard - Cook Medical - Cordis - Covidien - Edwards Lifesciences - Fresenius - Gambro - Kawasumi Laboratories - LeMaitre - MAKY - MEDRAD - Mar Cor - Medcomp - Medisystems (NxStage Medical) - Medivators - NxStage Medical - Rockwell - Teleflex Medical - Terumo, - Vascular - W. L. Gore For more information visit http://www.researchandmarkets.com/research/cb...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
NxStage Reports Record Fourth Quarter and Full-Year 2013 Financial Results
PR Newswire - Thu Feb 27, 6:31AM CST
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported record financial results for the three and twelve months ended December 31, 2013, that include revenue slightly above its recent guidance.
BrainStorm Receives Additional $600,000 Non-Dilutive Grant From Israel's Office of the Chief Scientist
Marketwire - Tue Feb 25, 8:15AM CST
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that BrainStorm Cell Therapeutics Ltd. was awarded an additional non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014 in the amount of $600,000. The grant is intended to support BrainStorm's clinical development for its innovative stem cell therapy candidate NurOwn(TM).
Nasdaq stocks posting largest percentage increases
AP - Fri May 09, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
NxStage Reports Record First Quarter 2014 Financial Results And Exceeds Guidance
PR Newswire - Thu May 08, 6:22AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported record first quarter financial results that exceed the top end of its guidance range.
8.1% Return Seen to Date on SmarTrend NxStage Medical Call (NXTM)
Comtex SmarTrend(R) - Wed May 07, 5:22PM CDT
SmarTrend identified a Downtrend for NxStage Medical (NASDAQ:NXTM) on March 28th, 2014 at $12.43. In approximately 1 month, NxStage Medical has returned 8.13% as of today's recent price of $11.42.
Technical Roundup on Health Care Stocks -- Research on Amarin, United Therapeutics, Hologic, and NxStage Medical
PR Newswire - Fri Apr 25, 1:10PM CDT
On Thursday, April 24, 2014, the NASDAQ Composite ended at 4,148.34, up 0.52%, the Dow Jones Industrial Average finished the day flat at 16,501.65, and the S&P 500 closed at 1,878.61, up 0.17%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.80, down 0.20%, while the index has advanced 0.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR), Hologic Inc. (NASDAQ: HOLX) and NxStage Medical Inc. (NASDAQ: NXTM). Free technical research on AMRN, UTHR, HOLX and NXTM can be downloaded upon signing up at:
NxStage Patient Enjoys Travel and Active Lifestyle
PR Newswire - Tue Apr 15, 7:15AM CDT
NxStage Medical Inc., (NASDAQ: NXTM), a leading manufacturer of innovative home dialysis products, is proud to share current NxStage patient Henning's story of resilience and strength. For Henning, who has spent his life pursuing active and athletic endeavors around the world, more frequent home hemodialysis (HHD) with the NxStage® System One(TM) proved to be a good personal fit. Henning, a Danish citizen, has regained control of his life thanks to home hemodialysis. Currently he and his wife spend the majority of their time in New Hampshire and travel with the NxStage System One.
FDA Recommendations, Study Publications, Recognitions, Agreements, and Acquisitions - Analyst Notes on MannKind, Acceleron, Steris, Retrophin, and NxStage Medical
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ: XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX), and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
NxStage® to Report First Quarter 2014 Financial Results
PR Newswire - Tue Apr 08, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the first quarter ended March 31, 2014, on Thursday, May 8, 2014, before the opening of the financial markets.
Equities Updates on Top Gainers -- Research on Fresh Market, Alliance Fiber Optic Products, NxStage Medical, and UQM Technologies
PR Newswire - Thu Apr 03, 7:59AM CDT
On Wednesday, April 02, 2014, the US markets saw a positive sentiment, with the NASDAQ Composite closing at 4,276.46, up 0.20%, the Dow Jones Industrial Average ending the session at 16,573.00, up 0.24% and the S&P 500 edging 0.29% higher to finish the trading session at 1,890.90. The session saw a positive impact from Consumer Discretionary, Materials and Industrials sectors along with a drag from Information Technology, and Utilities sectors. A number of stocks saw large movements, including The Fresh Market Inc. (NASDAQ: TFM), Alliance Fiber Optic Products Inc. (NASDAQ: AFOP), NxStage Medical Inc. (NASDAQ: NXTM) and UQM Technologies Inc. (NYSE MKT: UQM). Free technical research on TFM, AFOP, NXTM and UQM can be downloaded upon signing up at:
NxStage Wins 2014 American Red Cross Northeast Chapter Workplace Hero Award
PR Newswire - Mon Mar 31, 7:37AM CDT
NxStage Medical Inc., a leading manufacturer of home dialysis products, today announced the Company has been awarded the 2014 Workplace Hero Award by the Northeast Chapter of the American Red Cross. Recognized for its commitment to community service over the course of 2013, NxStage distinguished itself from industry peers through continuous efforts to provide support for the disadvantaged and dedication to preparing employees to volunteer in the event of local and national disasters. The American Red Cross Northeast Chapter presented the award to NxStage for the first time at the 12th Annual Community Heroes Breakfast at the Doubletree by Hilton in Danvers, Massachusetts on March 20, 2014.
Uptrend Call Working As NxStage Medical Stock Rises 10.4% (NXTM)
Comtex SmarTrend(R) - Thu Mar 27, 9:31AM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on January 9th, 2014 at $11.37. In approximately 3 months, NxStage Medical has returned 10.38% as of today's recent price of $12.55.
NxStage Establishes First Annual National Home Hemodialysis Day
PR Newswire - Thu Mar 20, 7:00AM CDT
To build awareness for National Kidney Month, NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the first annual National Home Hemodialysis Day taking place today, March 20, 2014. In partnership with local and national kidney patient organizations, NxStage is encouraging the more than 26 million Americans1 that may have kidney disease and their supporters to wear a green ribbon to spread the word about kidney disease treatment options including home hemodialysis. In conjunction with this campaign, the Company is launching a national patient-to-patient outreach program called NxStage® + One(TM). This innovative initiative is based on the premise that one-to-one communication is the most compelling way to spread the word about the benefits of home hemodialysis.
NxStage Medical Up 21.6% Since SmarTrend Uptrend Call (NXTM)
Comtex SmarTrend(R) - Wed Mar 19, 5:00PM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on January 9th, 2014 at $11.37. In approximately 2 months, NxStage Medical has returned 21.64% as of today's recent price of $13.83.
Uptrend Call Working As NxStage Medical Stock Rises 21.8% (NXTM)
Comtex SmarTrend(R) - Wed Mar 12, 11:06AM CDT
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on January 9th, 2014 at $11.37. In approximately 2 months, NxStage Medical has returned 21.81% as of today's recent price of $13.85.
Downgrade Alert for NxStage Medical (NXTM)
Comtex SmarTrend(R) - Tue Mar 11, 6:58AM CDT
NxStage Medical (NASDAQ:NXTM) was downgraded from Market Perform to Underperform at Wells Fargo today. The stock closed yesterday at $14.66 on volume of 1.3 million shares, above average daily volume of 497,000. In the past 52 weeks, NxStage Medical share prices have been bracketed by a low of $8.77 and a high of $15.00 and closed yesterday at $14.66, 67% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 2.2% while the 200-day MA has remained constant.
US Market for Dialysis Equipment and Concentrates
M2 - Thu Mar 06, 3:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/npv4t6/u_s_market_for) has announced the addition of the "U.S. Market for Dialysis Equipment and Concentrates" report to their offering. The Total Dialysis Device And Concentrates Market Will Grow To A Value Of Almost $2 Billion By 2020 The total dialysis device and concentrates market includes the markets for hemodialysis machines, dialysis catheters, dialysis concentrates, dialyzers, dialyzer reprocessing machines, bloodlines, AV fistula needles, AV grafts, declotting devices, guidewires, introducer sheaths and water treatment systems. The market will grow as a result of increased patient populations. The patient populations of traditional incenter hemodialysis, home hemodialysis (HHD) and peritoneal dialysis are expected to grow over the forecast period. There will also be strong growth in the dry concentrates and heat disinfectant water treatment system market. Scope of the Report - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback & Market Monitoring Reasons To Buy This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on a 'ground up' approach, which includes primary and secondary research methods. This report forecasts the development of the US market up to 2020. Key Topics Covered - Executive Summary - Research Methodology - US Dialysis Device And Concentrates Market - Hemodialysis Machine Market - Dialysis Catheter Market - Dialysis Concentrates Market - Dialyzer Market - Dialyzer Reprocessing Machine Market - Hemodialysis Bloodline And Tubing Set Market - Av Fistula Needle Market - Av Access Graft Market - Declotting Device Market - Introducer Sheath And Guidewire Market - Water Treatment System Market Companies Mentioned - AmeriWater - AngioDynamics - Argon Medical - Asahi Kasei Medical - B. Braun - Baxter - C. R. Bard - Cook Medical - Cordis - Covidien - Edwards Lifesciences - Fresenius - Gambro - Kawasumi Laboratories - LeMaitre - MAKY - MEDRAD - Mar Cor - Medcomp - Medisystems (NxStage Medical) - Medivators - NxStage Medical - Rockwell - Teleflex Medical - Terumo, - Vascular - W. L. Gore For more information visit http://www.researchandmarkets.com/research/np...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Shares of NXTM Up 25.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 05, 9:41AM CST
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on January 9th, 2014 at $11.37. In approximately 2 months, NxStage Medical has returned 25.95% as of today's recent price of $14.32.
U.S. Market for Dialysis Equipment and Concentrates (Executive Summary)
M2 - Fri Feb 28, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbwzlh/u_s_market_for) has announced the addition of the U.S. Market for Dialysis Equipment and Concentrates (Executive Summary) report to their offering. This executive summary relates to the report U.S. Market for Dialysis Equipment and Concentrates. The total dialysis device and concentrates market will grow to a value of almost $2 billion over the forecast period. The total dialysis device and concentrates market includes the markets for hemodialysis machines, dialysis catheters, dialysis concentrates, dialyzers, dialyzer reprocessing machines, bloodlines, AV fistula needles, AV grafts, declotting devices, guidewires, introducer sheaths and water treatment systems. The market will grow as a result of increased patient populations. The patient populations of traditional incenter hemodialysis, home hemodialysis (HHD) and peritoneal dialysis are expected to grow over the forecast period. There will also be strong growth in the dry concentrates and heat disinfectant water treatment system market. This report pertains to a forecast period of 10 years (2010 - 2020) for the U.S. market. Scope of the Report - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback & Market Monitoring Main Segments Included - U.S. Dialysis Device and Concentrates Market - Hemodialysis Machine Market - Dialysis Catheter Market - Dialysis Concentrates Market - Dialyzer Market - Dialyzer Reprocessing Machine Market - Hemodialysis Bloodline and Tubing Set Market - AV Fistula Needle Market - AV Access Graft Market - Declotting Device Market - Introducer Sheath and Guidewire Market - Water Treatment System Market Reasons To Buy This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on a 'ground up' approach, which includes primary and secondary research methods. * Please note this is an executive summary only. The full report is available for purchase by following the link below. Key Topics Covered: 1. Executive Summary 1.1 U.S. Dialysis Device And Concentrates Market 1.2 Hemodialysis Machine Market 1.3 Dialysis Catheter Market 1.4 Dialysis Concentrates Market 1.5 Dialyzer Market 1.6 Dialyzer Reprocessing Machine Market 1.7 Hemodialysis Bloodline And Tubing Set Market 1.8 Av Fistula Needle Market 1.9 Av Access Graft Market 1.10 Declotting Device Market 1.11 Introducer Sheath And Guidewire Market 1.12 Water Treatment System Market 1.13 Competitive Analysis Companies Mentioned: - AmeriWater - AngioDynamics - Argon Medical - Asahi Kasei Medical - B. Braun - Baxter - C. R. Bard - Cook Medical - Cordis - Covidien - Edwards Lifesciences - Fresenius - Gambro - Kawasumi Laboratories - LeMaitre - MAKY - MEDRAD - Mar Cor - Medcomp - Medisystems (NxStage Medical) - Medivators - NxStage Medical - Rockwell - Teleflex Medical - Terumo, - Vascular - W. L. Gore For more information visit http://www.researchandmarkets.com/research/cb...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
NxStage Reports Record Fourth Quarter and Full-Year 2013 Financial Results
PR Newswire - Thu Feb 27, 6:31AM CST
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported record financial results for the three and twelve months ended December 31, 2013, that include revenue slightly above its recent guidance.
BrainStorm Receives Additional $600,000 Non-Dilutive Grant From Israel's Office of the Chief Scientist
Marketwire - Tue Feb 25, 8:15AM CST
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that BrainStorm Cell Therapeutics Ltd. was awarded an additional non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014 in the amount of $600,000. The grant is intended to support BrainStorm's clinical development for its innovative stem cell therapy candidate NurOwn(TM).
